SLE, Sjögren’s and APS - treatment and SLE, Sjögren’s and APS - clinical aspects (other than treatment).

**OP0129**

**BELIMUM AFTER RITUXIMAB SIGNIFICANTLY REDUCED IGG ANTI-DS DNA ANTIBODY LEVELS AND PROLONGED TIME TO SEVERE FLARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

M. Shipa, A. Embleton-Thirsk, M. Parvaz, L. Santos Ribeiro, P. Muller, K. Chowdhury, D. Isenberg, C. Dore, C. Gordon, M. Ehrenstein

1. University College London, Department of Rheumatology, London, United Kingdom; 2. University College London, Comprehensive Clinical Trials Unit, London, United Kingdom; 3. University of Birmingham, Rheumatology Research Team - Inflammation and Ageing, Birmingham, United Kingdom

Background: B cell depletion with rituximab, an anti-CD20 mAb, has shown efficacy for systemic lupus erythematosus (SLE) in open-label studies but failed to meet primary endpoints in two randomised, placebo controlled trials. Rituximab increases BAFF levels which has been associated with subsequent lupus flares. We hypothesised that high BAFF levels after rituximab limit its effectiveness in SLE and that the anti-BAFF monoclonal antibody belimumab given immediately after rituximab could be a valuable therapeutic strategy.

Objectives: To assess the safety and obtain preliminary evidence for efficacy of belimumab following rituximab therapy in patients with SLE.

Methods: BEAT-LUPUS (Belimumab after B cell depletion in SLE) is a 52-week phase IIb, randomised, double-blind, placebo-controlled clinical trial investigating the safety and efficacy of intravenous belimumab after B cell depletion therapy (rituximab). The maximum permissible prednisolone dose throughout the trial was 20mg/day with encouragement to reduce by 50% from baseline by 6 months. The primary outcome measure was log IgG anti-dsDNA antibody serum levels at 52 weeks measured by ELISA. A linear regression ANCOVA model was fitted to evaluate the differences in 52-week anti-dsDNA levels between treatment arms adjusting for anti-dsDNA outcome measure was log IgG anti-dsDNA antibody serum levels at 52 weeks measured by ELISA. A linear regression ANCOVA model was fitted to evaluate the difference in 52-week anti-dsDNA levels between treatment arms adjusting for anti-dsDNA value at screening (before rituximab) and randomisation (4-8 weeks after the 1st infusion of rituximab), CD19 > 0.01 x 10^7/l at randomisation, and renal involvement at screening. Secondary outcomes included measures of disease activity and incidence of adverse events. B cell (CD19) counts were measured by flow cytometry. Intention to treat analysis was adopted. Full ethical and regulatory approval was obtained. A comprehensive description of the protocol and statistical analysis plan is available.

Results: 52 patients with active SLE received rituximab (2 infusions, 2 weeks apart) and then randomised to receive either belimumab (n=26) or placebo (n=26) 4-8 weeks after their 1st dose of rituximab. 32 patients completed trial treatment protocol (belimumab or placebo) through to 52 weeks, withdrawals were equally split between belimumab and placebo. There was a significant reduction in IgG anti-dsDNA antibody levels in patients treated with belimumab compared to placebo at 52 weeks (p<0.001, Figure 1); 43 patients were included in the intention to treat analysis at 52 weeks.

**Figure 1.** Serum IgG anti-dsDNA antibody levels (geometric means with 95% confidence intervals) in patients treated with rituximab, then randomised to belimumab or placebo at 1st trial infusion. An intention to treat linear regression ANCOVA model was fitted to evaluate the differences in 52-week anti-dsDNA between belimumab or placebo adjusting for baseline values and stratification factors. N= patient numbers who provided serum samples at time indicated. Kaplan-Meier curves demonstrated that belimumab reduced the risk of severe flare (BILAG A flare) compared to placebo (hazard ratio 0.27, 95% confidence interval 0.070-0.97, unadjusted log-rank p=0.03). There were 10 and 3 severe flares in the placebo and belimumab group respectively. There was no difference in baseline steroid dose over the course of the trial between belimumab and placebo. Belimumab did not increase the incidence of infections, serious or total adverse events, nor withdrawals due to adverse events compared to placebo. Belimumab significantly suppressed B cell repopulation at 52 weeks compared to placebo (p=0.001), but not total serum IgG.

Conclusion: This placebo controlled double blind trial met its primary endpoint, a significant reduction in IgG anti-dsDNA antibody levels, and demonstrated that belimumab prolongs the time to severe flare compared to placebo. These results suggest that belimumab after rituximab is a safe and effective treatment for patients with SLE and supports further development of this combination as a novel therapeutic strategy.

**REFERENCES:**


**Acknowledgements:** We acknowledge the important contribution of the BEAT Lupus Trial Steering Committee, the Data Monitoring Committee, the BEAT-LUPUS trial investigators, and all the patients participating in the trial or involved in its development.

**Disclosure of Interests:** Muhammad Shipa: None declared, Andrew Embleton-Thirsk: None declared, Mariae Parvaz: None declared, Liliana Santos Ribeiro: None declared, Patrick Muller: None declared, Kashfia Chowdhury: None declared, David Isenberg Speakers bureau: Paid by GSK to deliver educational talks, Consultant of: Received consultancy fees from GSK for attending advisory boards, Caroline Doré: None declared, Caroline Gordon Speakers bureau: Paid for educational speaker role by GSK, Consultant of: Received consultancy fees from GSK for attending advisory boards, Michael Ehrenstein Speakers bureau: Paid by GSK as a speaker in educational sessions, Consultant of: Received consultancy fees from GSK for attending advisory boards, Grant/research support from: GSK provided part of the funding for the BEAT-LUPUS trial.

**OP0130**

**COMPOSITE OF RELEVANT ENDPOINTS IN SJÖGREN’S SYNDROME (CRESS): A COMPREHENSIVE TOOL FOR CLINICAL TRIALS**


1. University Medical Centre Groningen and University of Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands; 2. University Medical Centre Groningen and University of Groningen, Ophthalmology, Groningen, Netherlands; 3. Queen Mary University of London, London, United Kingdom; 4. Queen Elizabeth Hospital, Rheumatology, Birmingham, United Kingdom; 5. John Hopkins University School of Medicine, Rheumatology, Baltimore, United States of America; 6. Bristol Myers Squibb, Brussels, Belgium; 7. Centre National de Référence des Maladies Auto-immunes et Systémiques rare Est/Sud-Ouest (RESS), Rhoës, Strasbourg, France; 8. Centre National de Référence des Maladies Auto-immunes et Systémiques rare Est/Sud-Ouest (RESS), Rheumatology, Strasbourg, France;

Background: Several large randomised controlled trials (RCTs) in primary Sjögren’s syndrome (pSS) failed to demonstrate drug efficacy.1-3 Many of these trials used ESSDAI as primary endpoint, showing large but similar response rates in active treatment and placebo groups.1,3,4 Given the heterogeneous nature of pSS, there is need for a composite endpoint including multiple clinically relevant parameters.

Objectives: To develop and validate the Composite of Relevant Endpoints in Sjögren’s Syndrome (CRESS).

Methods: A multi-centre, multi-speciality panel of 39 pSS experts selected clinically relevant items and measurements to include in the CRESS. Definition of response of CRESS items was based on clinical relevance, previously defined minimal clinically important improvement (MCII) and data of the single-centre ASAP-III (abatacept) trial.1 CRESS was validated in three independent RCTs: TRACTISS (rituximab) trial,